The company has entered in its second collaboration with MSD/Merck for its Phase 2 study ... www.tmepharma.com. TME Pharma® and the TME Pharma logo are registered trademarks.

Contentious hearings to consider Robert F. Kennedy Jr. to lead the Department of Health and Human Services this week have ...

ImaginAb, Inc., announces that it has entered into an agreement to sell a pipeline of next-generation therapeutic candidates, ...

LabConnect, a leading provider of central lab services and functional service provider solutions, is proud to announce the ...

Merck & Co. (NYSE:MRK) is a prominent American multinational pharmaceutical company many investors know for its brand-name drugs such as Keytruda, and the myriad of commercials the company shows on ...

Merck & Co. (MRK) stock lost over 9% yesterday on announcing a temporary shipment halt of its Gardasil vaccine to China. The ...

Merck (MRK) stock was mangled today after the pharmaceutical and vaccine company released its guidance for 2025. The company expects adjusted ...

Merck’s full-year 2025 revenue guidance fell short of what some analysts were expecting, at a range of $64.1 billion to $65.6 ...

Investors have taken to punishing pharma companies that appear unable to gauge demand for their top products. Consider Pfizer. The company’s inability to accurately project demand for its Covid-19 ...

(Reuters) - Merck said it will pause shipments of Gardasil to China through at least mid-year, as continued weak demand for ...

Merck operates in a highly competitive pharmaceutical landscape, particularly in oncology and PAH treatments. In the PAH space, the company faces competition from drugs such as Keros Therapeutics ...

Merck gained Winrevair in its $11.5 billion acquisition of Acceleron in 2021 and got it across the FDA finish line in March of 2024 based on results from the phase 3 STELLAR trial.